File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury

TitleProlonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury
Authors
KeywordsHeart failure
Myocardial function
Issue Date2009
PublisherAmerican Physiological Society. The Journal's web site is located at http://intl-ajpheart.physiology.org/
Citation
American Journal Of Physiology - Heart And Circulatory Physiology, 2009, v. 297 n. 2, p. H708-H717 How to Cite?
AbstractB-type natriuretic peptide (BNP) is an established first-line therapy for acute decompensated heart failure (HF), but its efficacy in preventing left ventricular (LV) remodeling after myocardial injury is unknown. The goal of this study was to evaluate the effects of BNP therapy on remodeling after ischemic injury in an awake canine model. Dogs were chronically instrumented for hemodynamics. Ischemia was created by daily coronary embolization (Embo; 3.1 × 10 4 beads/day) for 3 wk; 60 min after the first embolization, BNP (100 ng·kg -1·min -1; n = 6) or saline (control; n = 6) was continuously infused via a left atrial catheter for 3 wk. Hemodynamics and echocardiography were performed in an awake state at baseline, 3 wk after Embo + BNP infusion, and 4 wk after stopping Embo + BNP infusion. End-systolic elastance (Ees) and LV change in pressure over time (dP/dt) were preserved throughout Embo + BNP therapy versus control therapy (E es: 3.76 ± 1.01 vs. 1.41 ± 0.16 mmHg/ml; LV dP/dt: 2,417 ± 96 vs. 2,068 ± 95 mmHg/s; both P < 0.05 vs. control). LV end-diastolic dimension was significantly smaller in BNP-treated dogs compared with control dogs (4.29 ± 0.10 vs. 4.77 ± 0.17 cm), and ejection fraction was maintained in treated dogs vs. control dogs (53 ± 1% vs. 46 ± 2%) (both P < 0.05 vs. control). Cyclooxygenase (COX)-2 expression in terminal LV tissue was significantly reduced after BNP therapy. Treatment with continuous infusion of BNP preserved LV geometry, improved systolic function, and prevented the progression of systolic HF after persistent ischemic injury. Copyright © 2009 the American Physiological Society.
Persistent Identifierhttp://hdl.handle.net/10722/129216
ISSN
2015 Impact Factor: 3.324
2015 SCImago Journal Rankings: 1.823
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Science and Technology Commission of Shanghai Municipality, People's Republic of China08431903002
National Heart, Lung, and Blood InstituteT32-HL-07854
Funding Information:

J. Wang is partially supported by a grant (08431903002) from the Science and Technology Commission of Shanghai Municipality, People's Republic of China. This work was partially supported by National Heart, Lung, and Blood Institute Grant T32-HL-07854 (I. George).

References

 

DC FieldValueLanguage
dc.contributor.authorGeorge, Ien_HK
dc.contributor.authorMorrow, Ben_HK
dc.contributor.authorXu, Ken_HK
dc.contributor.authorYi, GHen_HK
dc.contributor.authorHolmes, Jen_HK
dc.contributor.authorWu, EXen_HK
dc.contributor.authorLi, Zen_HK
dc.contributor.authorProtter, AAen_HK
dc.contributor.authorOz, MCen_HK
dc.contributor.authorWang, Jen_HK
dc.date.accessioned2010-12-23T08:33:41Z-
dc.date.available2010-12-23T08:33:41Z-
dc.date.issued2009en_HK
dc.identifier.citationAmerican Journal Of Physiology - Heart And Circulatory Physiology, 2009, v. 297 n. 2, p. H708-H717en_HK
dc.identifier.issn0363-6135en_HK
dc.identifier.urihttp://hdl.handle.net/10722/129216-
dc.description.abstractB-type natriuretic peptide (BNP) is an established first-line therapy for acute decompensated heart failure (HF), but its efficacy in preventing left ventricular (LV) remodeling after myocardial injury is unknown. The goal of this study was to evaluate the effects of BNP therapy on remodeling after ischemic injury in an awake canine model. Dogs were chronically instrumented for hemodynamics. Ischemia was created by daily coronary embolization (Embo; 3.1 × 10 4 beads/day) for 3 wk; 60 min after the first embolization, BNP (100 ng·kg -1·min -1; n = 6) or saline (control; n = 6) was continuously infused via a left atrial catheter for 3 wk. Hemodynamics and echocardiography were performed in an awake state at baseline, 3 wk after Embo + BNP infusion, and 4 wk after stopping Embo + BNP infusion. End-systolic elastance (Ees) and LV change in pressure over time (dP/dt) were preserved throughout Embo + BNP therapy versus control therapy (E es: 3.76 ± 1.01 vs. 1.41 ± 0.16 mmHg/ml; LV dP/dt: 2,417 ± 96 vs. 2,068 ± 95 mmHg/s; both P < 0.05 vs. control). LV end-diastolic dimension was significantly smaller in BNP-treated dogs compared with control dogs (4.29 ± 0.10 vs. 4.77 ± 0.17 cm), and ejection fraction was maintained in treated dogs vs. control dogs (53 ± 1% vs. 46 ± 2%) (both P < 0.05 vs. control). Cyclooxygenase (COX)-2 expression in terminal LV tissue was significantly reduced after BNP therapy. Treatment with continuous infusion of BNP preserved LV geometry, improved systolic function, and prevented the progression of systolic HF after persistent ischemic injury. Copyright © 2009 the American Physiological Society.en_HK
dc.languageengen_US
dc.publisherAmerican Physiological Society. The Journal's web site is located at http://intl-ajpheart.physiology.org/en_HK
dc.relation.ispartofAmerican Journal of Physiology - Heart and Circulatory Physiologyen_HK
dc.rightsAmerican Journal of Physiology: Heart and Circulatory Physiology. Copyright © American Physiological Society.-
dc.rightsThis is an unofficial adaptation or translation of an article that appeared in a publication of the American Physiological Society. The American Physiological Society has not endorsed the content of this adaptation or translation, or the context of its use.-
dc.subjectHeart failureen_HK
dc.subjectMyocardial functionen_HK
dc.subject.meshHeart Failure - drug therapy - etiology - ultrasonography-
dc.subject.meshMyocardial Ischemia - drug therapy - etiology - ultrasonography-
dc.subject.meshNatriuretic Agents - blood - pharmacology-
dc.subject.meshNatriuretic Peptide, Brain - blood - pharmacology-
dc.subject.meshVentricular Remodeling - drug effects-
dc.titleProlonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injuryen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0363-6135&volume=297&issue=2&spage=H708&epage=717&date=2009&atitle=Prolonged+effects+of+B-Type+natriuretic+peptide+infusion+on+cardiac+remodeling+after+sustained+myocardial+injury-
dc.identifier.emailWu, EX:ewu1@hkucc.hku.hken_HK
dc.identifier.authorityWu, EX=rp00193en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1152/ajpheart.00661.2008en_HK
dc.identifier.pmid19525373-
dc.identifier.pmcidPMC2724214-
dc.identifier.scopuseid_2-s2.0-68049102295en_HK
dc.identifier.hkuros177162en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-68049102295&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume297en_HK
dc.identifier.issue2en_HK
dc.identifier.spageH708en_HK
dc.identifier.epageH717en_HK
dc.identifier.isiWOS:000268348200027-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridGeorge, I=12787442300en_HK
dc.identifier.scopusauthoridMorrow, B=14424375100en_HK
dc.identifier.scopusauthoridXu, K=37068180800en_HK
dc.identifier.scopusauthoridYi, GH=7101660739en_HK
dc.identifier.scopusauthoridHolmes, J=7403240348en_HK
dc.identifier.scopusauthoridWu, EX=7202128034en_HK
dc.identifier.scopusauthoridLi, Z=9247928600en_HK
dc.identifier.scopusauthoridProtter, AA=7003806029en_HK
dc.identifier.scopusauthoridOz, MC=7102364376en_HK
dc.identifier.scopusauthoridWang, J=8061150000en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats